2023-09-29 12:15:23
Biohaven's ALS drug fails to meet study goals
Sept 29 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd BHVN.N said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed to meet the main goal and secondary goals of a mid-to-late stage study.
The migraine drugmaker in May agreed to an $11.6 billion acquisition deal by Pfizer Inc PFE.N, which plans to spin off its non-migraine drugs into a new publicly traded company.
AD
AD
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
(([email protected]; www.twitter.com/Manaswrites15;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Continue read on nasdaq.com